FDA Approves Trikafta for Additional Cystic Fibrosis Variants
The FDA has expanded the approval of Vertex Pharmaceuticals’ TRIKAFTA, a cystic fibrosis (CF) treatment, to include individuals aged...
FDA Approves Braftovi for BRAF V600E Metastatic Colorectal Cancer
The FDA granted accelerated approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for treating metastatic colorectal...
JCR’s JR-142 Phase III Trial Launched in Japan
JCR Pharmaceuticals has initiated a Phase III clinical trial in Japan for JR-142 (redalsomatropin alfa), a long-acting growth hormone...
Zivo Reports Efficacy vs. Avian Flu
Zivo Bioscience’s recent study with the University of Delaware demonstrates that their proprietary algal-based active ingredients can potentially reduce...
Oncodesign Reacquires Rights to OPM-201 After Positive Phase 1 Trial
Oncodesign Precision Medicine (OPM) has regained full rights to its Parkinson’s disease treatment program, OPM-201, after Servier Laboratories shifted...
Mirailab Launches NMN Supplements in Singapore
MIRAILAB BIOSCIENCE Inc., a Tokyo-based company specializing in NMN supplements, has partnered with Global Ocean Distribution Pte Ltd to...
Ellipses Launches Pioneering Clinical Trial in Middle East
Ellipses Pharma has launched its first large-scale Phase 1/2 oncology clinical trial in the United Arab Emirates (UAE) for...
SCOPE 2025 Participant Engagement Awards Finalists Announced
The SCOPE Summit has revealed the six finalists for its highly anticipated 2025 Participant Engagement Awards, celebrating excellence in...
Tiximed Secures $2.65M Investment for Novel Oral Therapy Trials
TIXiMED, a clinical-stage pharmaceutical company, has secured a $2.65 million loan from the Helmsley Charitable Trust to advance its...
Tolerance Bio, Inc. Launches $20.2M Seed Round for Thymus-Based Therapies
Tolerance Bio, Inc., a biopharmaceutical company, has formed a Scientific Advisory Board and completed a $20.2 million seed financing...